Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa ndc

besponsa ndc

Перейти к контенту

Главное меню:

Разное
besponsa ndc
NDC 0008-0100 Besponsa Inotuzumab Ozogamicin, Codes Related to to NDC 0008-0100 Besponsa, Besponsa - RxList, 0008-0100 NDC - BESPONSA (INOTUZUMAB OZOGAMICIN), 0008-0100-01 NDC Code | Besponsa - hipaaspace.com, NDC 00008-0100 Besponsa - FindACode.com, , , .
In a female fertility and early embryonic development study, female rats were administered daily intravenous doses of inotuzumab ozogamicin up to 0.11 mg/m2 for 2 weeks before mating through Day 7 of pregnancy. An increase in the proportion of resorptions and decrease in the number of embryos and uterine weights were observed at the 0.11 mg/m2 dose level (approximately 2 times the exposure in patients at the maximum recommended dose, based on AUC). Additional findings in female reproductive organs occurred in repeat-dose studies and included decreased and uterine weights, and ovarian and uterine . Findings in male reproductive organs occurred in repeat-dose toxicology studies and included decreased testicular weights, testicular degeneration, hypospermia, and prostatic and atrophy. Testicular degeneration and hypospermia were nonreversible following a 4-week nondosing period. In the chronic studies of 26-weeks duration, adverse effects on reproductive organs occurred at ≥0.07 mg/m2 in male rats and at 0.73 mg/m2 in female monkeys [see Use In Specific Populations].. Besponsa with NDC 0008-0100 is a a human prescription drug product labeled by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc.. The generic name of Besponsa is inotuzumab ozogamicin.. NCD Codes that may be related to Besponsa with NDC 0008-0100 is a a human prescription drug product labeled by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc...
In clinical studies of BESPONSA in patients with relapsed or refractory ALL, the immunogenicity of BESPONSA was evaluated using an electrochemiluminescence (ECL)-based immunoassay to test for anti-inotuzumab ozogamicin antibodies. For patients whose sera tested positive for anti-inotuzumab ozogamicin antibodies, a cell-based luminescence assay was performed to detect neutralizing antibodies.. National Drug Code 0008-0100 is assigned to besponsa with active ingredient(s) inotuzumab ozogamicin and is labeled by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. This web page contains comprehensive information about NDC Code 0008-0100-01. “Besponsa ” (aka “Inotuzumab Ozogamicin”) is a human prescription drug product labeled by “Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.”.. CPT ® - Level I codes & modifiers HCPCS - Level II codes & modifiers CDT ® Codes - Dental "D" codes ICD-10-PCS Codes, guidelines, etc. APC - Ambulatory Pmt Class.. . .
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню